|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study显示文摘Background:China incurs an extremely low treatment coverage of multidrug-resistant tuberculosis(MDR-TB).This study aimed to understand the experience of MDR-TB patients on quality of health care,and the clinical impact through an up to six-year follow-up.Methods:Cohorts of MDR-TB patients were built in TB/MDR-TB designated hospitals in four regions of China from 2014 to 2015.Patients were followed up during treatment course,and yearly confirmation afterward until 2019.Delay in MDR-TB diagnosis and treatment was calculated upon bacteriological confirmation and treatment initiation.Risk factors for unfavourable outcomes were identified by multivariate logistic regression.Results:Among 1168 bacteriological-positive TB patients identified from a 12-million population,58(5.0%)MDR-TB cases were detected.The median delay for MDR-TB diagnosis was 90.0 days,with 13.8%having a delay above 180.0 days.MDR-TB treatment was only recommended to 19(32.8%)participants,while the rest continued with regimen for drug-susceptible TB.In MDR-TB treatment group,36.8%achieved treatment success,while the others had incomplete treatment(21.1%),loss to follow-up(36.8%)and TB relapse(5.3%).For non-MDR-TB treatment group,33.3%succeeded,25.6%relapsed,2.6%failed,23.1%died,and 15.4%were lost to follow-up.Overall,only 35.7%(20/56)of detected MDR-TB patients had favourable outcomes and higher education level was positively associated with it(adjusted odds ratio[aOR]:3.60,95%confidence interval[CI]:1.04-12.5).Conclusions:A large proportion of patients did not receive MDR-TB treatment and had unfavourable outcomes.Delayed MDR-TB diagnosis resulted in poor quality of MDR-TB care.Rapid diagnosis,regulated patient management and high-quality MDR-TB treatment should be enhanced in China. | Xu-Bin Zheng Vinod K.Diwan Qi Zhao Yi Hu Judith Bruchfeld Wei-Li Jiang Sven Hoffner Biao Xu | 2020 | Infectious Diseases of Poverty2020，9，4： | 5 |
| 2 | Cholinergic anti -inflammatory pathway activity and High Mobility Group Box - 1 ( HMGB1 ) serum levels in patients with rheumatoid arthritis 显示文摘 | Goldstein RS Bruchfeld A Yang L | 2007 | Mol Med2007，13，34： | 1 |
| 3 | Cholinergic anti-inflam-matory pathway activity and high mobility group box-1 (HMGB1) serum levels in patients with rheumatoid arthritis显示文摘 | Goldstein RS Bruchfeld A Yang L | 2007 | Mol Med2007，13，34： | 1 |
| 4 | Cholinergic anti-inflammatory pathway activity and high mobility group Box-1(HMGB1)serum levels in patients with rheumatoid arthritis显示文摘 | Goldstein R S Bruchfeld A Yang L | 2007 | Mol Med2007，13，34： | 1 |
| 5 | Rapid diagnosis of tuberculosis by detection mycobacterial lipoarabinomannan in urine显示文摘 | Hamasur B Bruchfeld J Haile M | 2001 | J Microbiol Methods2001，45，1： | 1 |
| 6 | ERA - EDTA ERBP advisory board, endorsement of the kidney disease improving global outcomes (KDIGO) hepatitis C guidelines: A European renal best practice (ERBP) position statement显示文摘 | Covic A Abramowicz D Bruchfeld A | 2009 | Nephrol Dial Transplant2009，24，： | 1 |
| 7 | Interferon and ribaliyin treatment in patients with hepatitis C- associated renal disease and renal insufficiency显示文摘 | BRUCHFELD A LINDAHL K STAHLEL M | 2003 | Nepnrol Dial Trans Plant2003，18，8： | 1 |
| 8 | Interferon and ribavi- rin treatment in patients with hepatitis C -associated renal disease and renal insufficiency显示文摘 | Bruchfeld A Lindahl K Stahle L | 2003 | Nephrol Dial Transplant2003，18，8： | 1 |
| 9 | Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis 显示文摘 | Bruchfeld A Goldstein R S Chavan S | 2010 | J Intern Med2010，268，1： | 1 |
| 10 | Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study) :a com- bination phase 3 study 显示文摘 | ROTH D NELSON D R BRUCHFELD A | 2015 | Lancet2015，386，10： | 1 |
| 11 | Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography显示文摘 | SVENSSON JO BRUCHFELD A SCHVARCZ R | 2000 | Ther Drug Monit2000，22，2： | 1 |
| 12 | Deoxys- pergualin in relapsing and refractory Wegener' s granulomatosis显示文摘 | Flossmann O Baslund B Bruchfeld A | 2009 | Ann Rheum Dis2009，68，： | 1 |
| 13 | High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C显示文摘 | Lindahl K Stable L Bruchfeld A | 2005 | Hepatology2005，41，2： | 1 |
| 14 | Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia显示文摘 | Lindahl K Schvarcz R Bruchfeld A | | 0，，： | 1 |
| 15 | Cholinergic anti- inflammatory pathway activity and high mobility group Box- 1 (HMGB1) serum levels in patients with rheumatoid arthritis显示文摘 | Goldstein RS Bruchfeld A Yang L | 2007 | Moc Med2007，13，34： | 1 |
| 16 | Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study):a combination phase 3 study显示文摘 | Roth D Nelson D R Bruchfeld A | 2015 | Lancet2015，386，10003： | 1 |
| 17 | Rituximab in adult minimal change disease and focal segmental glomernlosclerosis 显示文摘 | Kronbichler A and Bruchfeld A | 2014 | Nephron Clin Pract2014，128，34： | 1 |
| 18 | High mobility group box protein-i correlates with renal function in chronic kidney disease(CKD)显示文摘 | Annette Bruchfeld Abdul Rashid Qureshi Bengt Lindholm | 2008 | Mol Med2008，14，： | 1 |
| 19 | Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients显示文摘 | Bruchfeld A Lindahl K Reichard O | 2006 | J Viral Hepat2006，13，： | 1 |
| 20 | Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis显示文摘 | Davies Forsman L Giske C G Bruchfeld J | 2015 | Antimicrobial agents and chemotherapy2015，59，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员